227 related articles for article (PubMed ID: 10640900)
1. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
Krassas GE; Pontikides N; Kaltsas T
Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
3. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
4. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
6. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
7. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
8. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
[TBL] [Abstract][Full Text] [Related]
11. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
14. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
15. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
Mallea-Gil MS; Cristina C; Perez-Millan MI; Villafañe AM; Ballarino C; Stalldecker G; Becu-Villalobos D
Endocr Pathol; 2009; 20(1):35-40. PubMed ID: 19172414
[TBL] [Abstract][Full Text] [Related]
16. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
17. Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
Tasan E; Hanimoglu H; Turgut S; Ilhan MM; Evran S; Kaynar MY
Neuro Endocrinol Lett; 2015; 36(1):28-30. PubMed ID: 25789596
[TBL] [Abstract][Full Text] [Related]
18. Pons herniation into skull base after cabergoline therapy of giant prolactinoma.
Moles Herbera J; Rivero Celada D; Montejo Gañan I; Fustero de Miguel D; Fuentes Uliaque C; Vela Marín AC
Pituitary; 2015 Feb; 18(1):68-71. PubMed ID: 24522845
[TBL] [Abstract][Full Text] [Related]
19. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
20. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
